Evidence map›Paper›PMID 39291021›Full record

ArticleACS medicinal chemistry letters2024

Synthesis and Optimization of Small Molecule Inhibitors of Prostate Specific Antigen.

Jeffery A Erickson, Ravikumar Jimmidi, Prashanth Anamthathmakula, Xuan Qin, Jian Wang, Leyi Gong, Jaehyeon Park, Gary Koolpe, Caitlin Tan, Martin M Matzuk and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Drug Discovery Strategies for Kallikrein-Related Peptidases.International journal of molecular sciences · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jeffery A EricksonObstetrics, Gynecology and Women's Health, School of Medicine, University of Missouri - Columbia, Columbia, Missouri 65211, United States.
Ravikumar JimmidiCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.
Prashanth AnamthathmakulaSchool of Medicine, University of Missouri - Kansas City, Kansas City, Missouri 64108, United States.
Xuan QinCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.ORCID https://orcid.org/0000-0003-3728-5911
Jian WangCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.ORCID https://orcid.org/0009-0000-9178-1225
Leyi GongDepartment of Medicinal and Synthetic Chemistry, Bioscience Division, SRI International, Menlo Park, California 94025, United States.
Jaehyeon ParkDepartment of Medicinal and Synthetic Chemistry, Bioscience Division, SRI International, Menlo Park, California 94025, United States.
Gary KoolpeDepartment of Medicinal and Synthetic Chemistry, Bioscience Division, SRI International, Menlo Park, California 94025, United States.
Caitlin TanDepartment of Medicinal and Synthetic Chemistry, Bioscience Division, SRI International, Menlo Park, California 94025, United States.
Martin M MatzukCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.ORCID https://orcid.org/0000-0002-1445-8632
Feng LiCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.
Srinivas ChamakuriCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.ORCID https://orcid.org/0000-0002-7586-4992
Wipawee WinuthayanonObstetrics, Gynecology and Women's Health, School of Medicine, University of Missouri - Columbia, Columbia, Missouri 65211, United States.ORCID https://orcid.org/0000-0002-5196-8471

Funding

Functional analysis of novel testis-expressed secreted and transmembrane proteinsR01HD088412 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI MARTIN M. MATZUK · 2016 to 2026
$4.5M
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptiveR01HD108198 · NICHD · WASHINGTON STATE UNIVERSITY · PI MARTIN M. MATZUK, OV D SLAYDEN · 2022 to 2026
$3.7M
Elucidating Chemical Features that Block or Facilitate Passage across the Blood-Testis and/or Blood-Epidydimal Barriers in MiceR33HD099995 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LI, FENG · 2022 to 2024
$1.7M
NICHD NIH HHS HHSN275201800007CNICHD NIH HHS R01 HD088412NICHD NIH HHS R01 HD108198NICHD NIH HHS R33 HD099995
6 · The paper itself

Abstract

Semen liquefaction is a postejaculation process that transforms semen from a gel-like (coagulated) form to a water-like consistency (liquefied). This process is primarily regulated by serine proteases from the prostate gland, most prominently, prostate-specific antigen (PSA; KLK3). Inhibiting PSA activity has the potential to impede liquefaction of human semen, presenting a promising target for nonhormonal contraception in the female reproductive tract. This study employed triazole B1 as a starting compound. Through systematic design, synthesis, and optimization, we identified compound

Identifiers

PMID39291021
PMCPMC11403753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.